Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

IMMU-132 for Metastatic Urothelial Cancer

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

Disease Types: Bladder

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

For more information:

https://clinicaltrials.gov/ct2/show/NCT03547973?term=IMMU-132-06&draw=2&rank=1